Market Closed -
Australian S.E.
02:10:46 2024-05-10 EDT
|
5-day change
|
1st Jan Change
|
0.68
AUD
|
+7.09%
|
|
+10.57%
|
+19.30%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
167.1
|
635.2
|
468.6
|
387.4
|
256.9
|
450.7
|
-
|
-
|
Enterprise Value (EV)
1 |
145.6
|
573.5
|
306.7
|
322.7
|
119.9
|
604.4
|
662.5
|
353.5
|
P/E ratio
|
-4.66
x
|
-23.3
x
|
-6.88
x
|
-2.87
x
|
-1.11
x
|
-1.49
x
|
-2.11
x
|
-6.18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
183
x
|
786
x
|
4,981
x
|
1,343
x
|
433
x
|
489
x
|
25.8
x
|
2.83
x
|
EV / Revenue
|
159
x
|
709
x
|
3,260
x
|
1,119
x
|
202
x
|
656
x
|
38
x
|
2.22
x
|
EV / EBITDA
|
-4.1
x
|
-23
x
|
-4.46
x
|
-2.31
x
|
-0.52
x
|
-2.29
x
|
-3.13
x
|
-231
x
|
EV / FCF
|
-6.01
x
|
-65.2
x
|
-4.9
x
|
-3.12
x
|
-0.65
x
|
-2.36
x
|
-3.16
x
|
3.17
x
|
FCF Yield
|
-16.6%
|
-1.53%
|
-20.4%
|
-32%
|
-155%
|
-42.4%
|
-31.7%
|
31.6%
|
Price to Book
|
3.36
x
|
6.15
x
|
2.53
x
|
-
|
-27.1
x
|
-2.78
x
|
-2.76
x
|
5.53
x
|
Nbr of stocks (in thousands)
|
249,415
|
269,158
|
351,004
|
352,153
|
467,159
|
662,809
|
-
|
-
|
Reference price
2 |
0.6700
|
2.360
|
1.335
|
1.100
|
0.5500
|
0.6800
|
0.6800
|
0.6800
|
Announcement Date
|
19-08-08
|
20-08-27
|
21-08-29
|
22-08-29
|
23-08-30
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.9148
|
0.8084
|
0.0941
|
0.2884
|
0.5932
|
0.9219
|
17.45
|
159
|
EBITDA
1 |
-35.51
|
-24.92
|
-68.79
|
-139.8
|
-230.9
|
-263.7
|
-211.9
|
-1.533
|
EBIT
1 |
-35.55
|
-25.06
|
-68.94
|
-139.9
|
-231
|
-276.8
|
-231.8
|
-54.83
|
Operating Margin
|
-3,885.6%
|
-3,100.21%
|
-73,284.21%
|
-48,510.06%
|
-38,939.69%
|
-30,023.98%
|
-1,328.45%
|
-34.48%
|
Earnings before Tax (EBT)
1 |
-35.55
|
-25.06
|
-68.94
|
-143.6
|
-228.6
|
-291.7
|
-253.2
|
-103
|
Net income
1 |
-20.91
|
-16.53
|
-62.17
|
-134.5
|
-219.5
|
-277.6
|
-224.5
|
-47.21
|
Net margin
|
-2,285.65%
|
-2,044.67%
|
-66,086.21%
|
-46,640.39%
|
-36,991.82%
|
-30,113.55%
|
-1,286.2%
|
-29.7%
|
EPS
2 |
-0.1437
|
-0.1014
|
-0.1940
|
-0.3826
|
-0.4958
|
-0.4578
|
-0.3219
|
-0.1100
|
Free Cash Flow
1 |
-24.2
|
-8.79
|
-62.59
|
-103.4
|
-185.7
|
-256.2
|
-209.9
|
111.6
|
FCF margin
|
-2,645.62%
|
-1,087.26%
|
-66,532.24%
|
-35,854.05%
|
-31,310%
|
-27,796.08%
|
-1,202.81%
|
70.16%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-08-08
|
20-08-27
|
21-08-29
|
22-08-29
|
23-08-30
|
-
|
-
|
-
|
Fiscal Period: June |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
0.2731
|
0.5353
|
0.3143
|
-0.1919
|
-
|
-0.0661
|
1.914
|
0.2898
|
3.082
|
0.1486
|
EBITDA
|
-11.51
|
-13.41
|
-18.43
|
-
|
-
|
-
|
-
|
-
|
-141.6
|
-
|
EBIT
1 |
-11.58
|
-13.48
|
-38.51
|
-16.15
|
-56.24
|
-83.02
|
-114
|
-104.3
|
-141.7
|
-163.4
|
Operating Margin
|
-4,239.37%
|
-2,518.97%
|
-12,251.44%
|
8,413.07%
|
-
|
125,676.02%
|
-5,954.51%
|
-35,989.85%
|
-4,597.95%
|
-109,896.59%
|
Earnings before Tax (EBT)
1 |
-11.47
|
-13.6
|
-38.51
|
-16.15
|
-
|
-84.77
|
-116.1
|
-106.7
|
-
|
-150.8
|
Net income
1 |
-7.62
|
-8.909
|
-34.98
|
-10.32
|
-
|
-79.86
|
-113.1
|
-100.7
|
-148.2
|
-152.5
|
Net margin
|
-2,789.99%
|
-1,664.38%
|
-11,130.55%
|
5,375.53%
|
-
|
120,894.81%
|
-5,908.29%
|
-34,760.84%
|
-4,807.68%
|
-102,607.06%
|
EPS
2 |
-
|
-
|
-0.1175
|
-0.0240
|
-0.1487
|
-0.2270
|
-0.2422
|
-0.2416
|
-0.2500
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-25
|
20-08-27
|
21-02-21
|
21-08-29
|
22-02-27
|
22-08-29
|
23-02-22
|
23-08-30
|
24-02-28
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
154
|
212
|
-
|
Net Cash position
1 |
21.5
|
61.8
|
162
|
64.7
|
137
|
-
|
-
|
97.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.583
x
|
-0.999
x
|
-
|
Free Cash Flow
1 |
-24.2
|
-8.79
|
-62.6
|
-103
|
-186
|
-256
|
-210
|
112
|
ROE (net income / shareholders' equity)
|
-60.4%
|
-34.5%
|
-50.4%
|
-101%
|
-677%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-49.9%
|
-34.5%
|
-
|
-93.5%
|
-180%
|
-
|
-
|
-
|
Assets
1 |
41.87
|
47.96
|
-
|
143.8
|
122.2
|
-
|
-
|
-
|
Book Value Per Share
2 |
0.2000
|
0.3800
|
0.5300
|
-
|
-0.0200
|
-0.2400
|
-0.2500
|
0.1200
|
Cash Flow per Share
2 |
-0.1700
|
-0.0500
|
-0.2000
|
-
|
-0.4200
|
-0.3800
|
-0.2500
|
0.3100
|
Capex
1 |
0.02
|
0.01
|
0.02
|
-
|
0.03
|
0.02
|
0.02
|
0.01
|
Capex / Sales
|
1.98%
|
0.9%
|
18.51%
|
-
|
5.7%
|
2.45%
|
0.09%
|
0.01%
|
Announcement Date
|
19-08-08
|
20-08-27
|
21-08-29
|
22-08-29
|
23-08-30
|
-
|
-
|
-
|
Last Close Price
0.68
AUD Average target price
0.8974
AUD Spread / Average Target +31.97% Consensus |
1st Jan change
|
Capi.
|
---|
| +19.30% | 298M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|